TY - JOUR A1 - Alt, Helmut T1 - Energietarifstruktur in Ostdeutschland JF - Energiewirtschaftliche Tagesfragen : et ; Zeitschrift für Energiewirtschaft, Recht, Technik und Umwelt Y1 - 1990 SN - 0013-743X VL - Bd. 40 IS - H. 11 SP - 782 EP - 788 ER - TY - JOUR A1 - Alt, Helmut T1 - Effektivzins und APR JF - Die Bank : Zeitschrift für Bankpolitik und Bankpraxis Y1 - 1991 SN - 0342-3182 N1 - Printausg. in der Bibliothek vorhanden: 43 Z 227 VL - Jg. 31 IS - H. 4 SP - 230 EP - 231 ER - TY - JOUR A1 - Alt, Helmut T1 - Möglichkeiten der CO2-Minderung "alternativ" betrachtet JF - Etz : Elektrotechnik & Automation Y1 - 1992 SN - 0170-1711 VL - Bd. 113 IS - H. 6-7 SP - 400 ER - TY - JOUR A1 - Alt, Helmut T1 - Netzimpedanz- und Oberschwingungsberechnung in Netzen der öffentlichen Stromversorgung JF - Elektrizitätswirtschaft Y1 - 1995 SN - 0013-5496 VL - Bd. 94 IS - H. 4 SP - 166 EP - 174 ER - TY - JOUR A1 - Alt, Helmut T1 - 1,45 Mrd. DM für die Kohlevergasung JF - Energiewirtschaftliche Tagesfragen Y1 - 1974 SN - 0720-6240 VL - 24 IS - 5 SP - 243 EP - 244 PB - VDE-Verlag CY - Berlin ER - TY - JOUR A1 - Alt, Helmut T1 - Renditevergleich zwischen Immobilien und Festverzinslichen JF - Die Bank Y1 - 1992 SN - 0342-3182 IS - H. 2 SP - 91 EP - 92 ER - TY - JOUR A1 - Alt, Helmut T1 - Elektro-Brikett-Zentralspeicherheizung soll die Spitzenlast der EVU schonen JF - Energiewirtschaftliche Tagesfragen Y1 - 1975 SN - 0720-6240 VL - 25 IS - 4 SP - 148 EP - 149 PB - VDE-Verlag CY - Berlin ER - TY - JOUR A1 - Alt, Helmut T1 - Ab 1975 Uranerz aus Rabbit-Lake JF - Energiewirtschaftliche Tagesfragen Y1 - 1974 SN - 0720-6240 VL - 24 IS - 1/2 SP - 34 PB - VDE-Verlag CY - Berlin ER - TY - JOUR A1 - Alnemer, Momin Sami Mohammad A1 - Kotliar, Konstantin A1 - Neuhaus, Valentin A1 - Pape, Hans-Christoph A1 - Ciritsis, Bernhard D. T1 - Cost-effectiveness analysis of surgical proximal femur fracture prevention in elderly: a Markov cohort simulation model JF - Cost Effectiveness and Resource Allocation N2 - Background Hip fractures are a common and costly health problem, resulting in significant morbidity and mortality, as well as high costs for healthcare systems, especially for the elderly. Implementing surgical preventive strategies has the potential to improve the quality of life and reduce the burden on healthcare resources, particularly in the long term. However, there are currently limited guidelines for standardizing hip fracture prophylaxis practices. Methods This study used a cost-effectiveness analysis with a finite-state Markov model and cohort simulation to evaluate the primary and secondary surgical prevention of hip fractures in the elderly. Patients aged 60 to 90 years were simulated in two different models (A and B) to assess prevention at different levels. Model A assumed prophylaxis was performed during the fracture operation on the contralateral side, while Model B included individuals with high fracture risk factors. Costs were obtained from the Centers for Medicare & Medicaid Services, and transition probabilities and health state utilities were derived from available literature. The baseline assumption was a 10% reduction in fracture risk after prophylaxis. A sensitivity analysis was also conducted to assess the reliability and variability of the results. Results With a 10% fracture risk reduction, model A costs between $8,850 and $46,940 per quality-adjusted life-year ($/QALY). Additionally, it proved most cost-effective in the age range between 61 and 81 years. The sensitivity analysis established that a reduction of ≥ 2.8% is needed for prophylaxis to be definitely cost-effective. The cost-effectiveness at the secondary prevention level was most sensitive to the cost of the contralateral side’s prophylaxis, the patient’s age, and fracture treatment cost. For high-risk patients with no fracture history, the cost-effectiveness of a preventive strategy depends on their risk profile. In the baseline analysis, the incremental cost-effectiveness ratio at the primary prevention level varied between $11,000/QALY and $74,000/QALY, which is below the defined willingness to pay threshold. Conclusion Due to the high cost of hip fracture treatment and its increased morbidity, surgical prophylaxis strategies have demonstrated that they can significantly relieve the healthcare system. Various key assumptions facilitated the modeling, allowing for adequate room for uncertainty. Further research is needed to evaluate health-state-associated risks. KW - Hip fractures KW - Prevention KW - Geriatric KW - Cost-effectiveness KW - Prophylaxis Y1 - 2023 U6 - https://doi.org/10.1186/s12962-023-00482-4 SN - 1478-7547 N1 - Corresponding author: Momin S. Alnemer IS - 21, Article number: 77 PB - Springer Nature ER - TY - JOUR A1 - Almajhdi, Fahad N. A1 - Senger, Tilo A1 - Amer, Haitham M. A1 - Gissmann, Lutz A1 - Öhlschläger, Peter T1 - Design of a highly effective therapeutic HPV16 E6/E7-specific DNA vaccine: optimization by different ways of sequence rearrangements (Shuffling) JF - PLOS one N2 - Persistent infection with the high-risk Human Papillomavirus type 16 (HPV 16) is the causative event for the development of cervical cancer and other malignant tumors of the anogenital tract and of the head and neck. Despite many attempts to develop therapeutic vaccines no candidate has entered late clinical trials. An interesting approach is a DNA based vaccine encompassing the nucleotide sequence of the E6 and E7 viral oncoproteins. Because both proteins are consistently expressed in HPV infected cells they represent excellent targets for immune therapy. Here we report the development of 8 DNA vaccine candidates consisting of differently rearranged HPV-16 E6 and E7 sequences within one molecule providing all naturally occurring epitopes but supposedly lacking transforming activity. The HPV sequences were fused to the J-domain and the SV40 enhancer in order to increase immune responses. We demonstrate that one out of the 8 vaccine candidates induces very strong cellular E6- and E7- specific cellular immune responses in mice and, as shown in regression experiments, efficiently controls growth of HPV 16 positive syngeneic tumors. This data demonstrates the potential of this vaccine candidate to control persistent HPV 16 infection that may lead to malignant disease. It also suggests that different sequence rearrangements influence the immunogenecity by an as yet unknown mechanism. Y1 - 2014 U6 - https://doi.org/10.1371/journal.pone.0113461 SN - 1932-6203 VL - 11 IS - 9 PB - PLOS CY - San Francisco ER -